Biotech Values

[genisi]

VRTX - interim analysis of data from 94 patients from Study 107

http://investors.vrtx.com/releasedetail.cfm?ReleaseID=419250

* 57% of prior treatment null responder patients achieved an SVR with a 48-week telaprevir-based regimen
* 90% of prior treatment relapsers and 55% of prior treatment partial responders achieved an SVR with 24-week or 48-week telaprevir-based regimens
* Results provide further support for the ongoing Phase 3 registration study, REALIZE, in treatment-failure patients